Is McKesson Corporation (MCK) a good stock to buy?

Olyth's institutional analysis of MCK reveals an Altman Z-Score of 5.95 and a Piotroski F-Score of 7/9. These metrics, combined with its 5-year revenue trend ($359.05B most recent), help investors decide if MCK fits their risk profile.

What is the current P/E ratio for MCK?

As of the latest trading session, McKesson Corporation (MCK) has a trailing P/E ratio of 24.32.

Who is the CEO of McKesson Corporation?

The current Chief Executive Officer of McKesson Corporation is Brian S. Tyler.

What was MCK's revenue for the last 5 years?

According to its latest income statements, McKesson Corporation reported annual revenues of $359.05B (2025), $308.95B (2024), $276.71B (2023), $263.97B (2022), $238.23B (2021) respectively.

Does MCK pay a dividend?

McKesson Corporation currently pays a dividend to its shareholders, with a trailing dividend yield of 0.37%.

How much debt and cash flow does MCK have?

In its latest reporting period, McKesson Corporation generated $5.23B in Free Cash Flow against a total debt load of $7.39B.

What is the Price-to-Book (P/B) ratio of McKesson Corporation?

The Price-to-Book (P/B) ratio for McKesson Corporation (MCK) is currently -81.32.

What is the Price-to-Sales (P/S) ratio of MCK?

Based on trailing twelve-month data, McKesson Corporation (MCK) trades at a Price-to-Sales (P/S) ratio of 0.27.

What is McKesson Corporation's Return on Equity (ROE)?

McKesson Corporation (MCK) has a Return on Equity (ROE) of -245.27%, representing its profitability relative to shareholder equity.

MCK

McKesson Corporation · Healthcare

856.77

3.11%(-27.51)

Prev. Close

930.00

8.55%(+73.23)

Pre-market

Last Updated: — ET

52W L: $637.0052W H: $999.00

$858.75

CHG-53.24 (-5.84%)

H$959.95

L$847.32

VOL13M

MCK (1h)

Company Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The International segment offers distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The RxTS segment serves biopharma and life sciences partners and patients to address medication challenges for patients throughout their journeys; connects pharmacies, providers, payers, and biopharma companies to deliver innovative access and adherence solutions; and provides third-party logistics and wholesale distribution support solutions. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.

Sector

Healthcare

Industry

Medical - Distribution

Employees

44,000

IPO Date

1994-11-10

Beta

0.42

Websitewww.mckesson.com↗

MCK

Florida Trust Wealth Management Co Sells 715 Shares of McKesson Corporation $MCK

McKesson (MCK) Outperforms Broader Market: What You Need to Know

Blue Trust Inc. Sells 645 Shares of McKesson Corporation $MCK

Here is What to Know Beyond Why McKesson Corporation (MCK) is a Trending Stock

Burns Matteson Capital Management LLC Invests $575,000 in McKesson Corporation $MCK

Exchange Traded Concepts LLC Sells 755 Shares of McKesson Corporation $MCK